SEARCH

SEARCH BY CITATION

References

  • 1
    Pendino GM, Mariano A, Surace P et al. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. Hepatology 2005; 41: 11519.
  • 2
    Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 91723.
  • 3
    Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002; 288: 17237.
  • 4
    Chen DS, Sung JL. Hepatitis B virus infection and chronic liver diseases in Taiwan. Acta Hepatogastroenterol. 1978; 25: 42330.
  • 5
    Lee SD, Chan CY, Wang YJ et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991; 13: 8303.
  • 6
    Katkov WN, Friedman LS, Cody H et al. Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C. Ann. Intern. Med. 1991; 115: 8824.
  • 7
    Chang CJ, Ko YC, Liu HW. Serum alanine aminotransferase levels in relation to hepatitis B and C virus infections among drug abusers in an area hyperendemic for hepatitis B. Dig. Dis. Sci. 2000; 45: 194952.
  • 8
    Hultcrantz R, Gabrielsson N. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionuclide imaging and liver biopsy. J. Intern. Med. 1993; 233: 712.
  • 9
    Mendler MH, Bouillet P, LeSidaner A et al. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J. Hepatol. 1998; 28: 78594.
  • 10
    Saverymuttu SH, Joseph AE, Maxwell JD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ 1986; 292: 1315.
  • 11
    Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J. Gastroenterol. Hepatol. 2002; 17: 113643.
  • 12
    Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 74550.
  • 13
    Scatarige JC, Scott WW, Donovan PJ, Siegelmann SS, Sanders RC. Fatty infiltration of the liver: ultrasonographic and computed tomographic correlation. J. Ultrasound Med. 1984; 3: 914.
  • 14
    Choudhury J, Sanyal AJ. Clinical aspects of fatty liver disease. Semin. Liver Dis. 2004; 24: 34962.
  • 15
    Sanyal AJ, Contos MJ, Sterling RK et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am. J. Gastroenterol. 2003; 98: 206471.
    Direct Link:
  • 16
    Marchesini G, Brizi M, Morselli-Labate AM et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am. J. Med. 1999; 107: 4505.
  • 17
    Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 3739.
  • 18
    Bugianesi E, Manzini P, D’Antico S et al. Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver. Hepatology 2004; 39: 17987.
  • 19
    Chen DS. Natural history of chronic hepatitis B virus infection: new light on an old story. J. Gastroenterol. Hepatol. 1993; 8: 4705.
  • 20
    Wang CS, Chang TT, Chou P. Differences in risk factors for either a hepatitis B carrier or anti-hepatitis C+ in a hepatoma-hyperendemic area in rural Taiwan. J. Clin. Epidemiol. 1998; 51: 7338.
  • 21
    Maio G, D’Argenio P, Stroffolini T et al. Hepatitis C virus infection and alanine transaminase levels in the general population: a survey in a southern Italian town. J. Hepatol. 2000; 33: 11620.
  • 22
    Hayashi N, Kanto T, Takehara T. Immunopathogenesis of type C hepatitis: dendritic cell in HCV infection. J. Gastroenterol. Hepatol. 2004; 19: S84S87.
  • 23
    Soguero C, Joo M, Chianese-Bullock KA, Nguyen DT, Tung K, Hahn YS. Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model. J. Virol. 2002; 76: 934554.
  • 24
    Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 2002; 36: 72936.
  • 25
    Fiore G, Fera G, Napoli N, Vella F, Schiraldi O. Liver steatosis and chronic hepatitis C: a spurious association? Eur. J. Gastroenterol. Hepatol. 1996; 8: 1259.
  • 26
    Liu CJ, Jeng YM, Chen PJ et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antiviral Ther. 2005; 10: 40515.
  • 27
    Perlemuter G, Sabile A, Letteron P et al. Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. FASEB J. 2002; 16: 18594.
  • 28
    Yamaguchi A, Tazuma S, Nishioka T et al. Hepatitis C virus core protein modulates fatty acid metabolism and thereby causes lipid accumulation in the liver. Dig. Dis. Sci. 2005; 50: 136171.
  • 29
    Kao JH, Chen PJ, Lai MY et al. Genotypes of hepatitis C virus in Taiwan and the progression of liver disease. J. Clin. Gastroenterol. 1995; 21: 2337.
  • 30
    Liu CJ, Chen PJ, Shau WY, Kao JH, Lai MY, Chen DS. Clinical aspects and outcomes of volunteer blood donors testing positive for hepatitis-C virus infection in Taiwan: a prospective study. Liver Int. 2003; 23: 14855.